This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment

Herbert Y. Meltzer, MD

Published: September 1, 2002

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

With the development of the atypical antipsychotic drugs—clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and more to follow—has come an increasing understanding of the metabolic and cardiovascular side effects of these drugs, which have an impact on morbidity and mortality. These drugs represent major advances in the treatment of schizophrenia, bipolar disorder, psychotic depression, and senile psychoses, but differ in side effects. As with all drugs, this class has both its benefits and its risks, and many of those risks have only come to light recently.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 63

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...